Loading...
•
Jun 30, 2020
Collegium Q2 2020 Earnings Report
Collegium reported net income of $8.1 million and non-GAAP net income of $33.2 million.
Key Takeaways
Collegium Pharmaceutical, Inc. reported strong financial results for the second quarter of 2020, driven by Xtampza ER revenue growth and the Nucynta acquisition, which generated meaningful cash flow from operations and enabled the company to begin paying down debt.
Collegium delivered strong financial results in the second quarter of 2020.
Xtampza ER total prescriptions grew to 141,678, representing a 22% increase over the prior year quarter.
Xtampza ER market share of the oxycodone extended-release market was 23.5%.
Nucynta ER market share of the branded extended-release market grew to 6.2%.
Revenue by Segment
Forward Guidance
The company has not provided a reconciliation of its full-year 2020 guidance for non-GAAP adjusted income to the most directly comparable forward-looking GAAP measure because it is unable to predict, without unreasonable efforts, the timing and amount of items that would be included such a reconciliation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...